News & Press

Yair Holtzman, Partner and Leader of Anchin’s R&D Tax Credits and Life Sciences groups, was recently featured in a Modern Healthcare article highlighting the new tax law’s significant incentives for MedTech companies.

In the article, Yair emphasizes that immediate deductions for domestic R&D expenses give companies greater control over cash flow, improve tax planning, and support better investment strategies in hiring, equipment, and U.S.-based research. He also notes that the incentive may encourage companies to accelerate or relocate R&D activities to the United States. To read more about these incentives and how the new tax law benefits the MedTech industry, please click here.